References |
1 |
Fenofibrate was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
|
2 |
In?vitro metabolism of fenofibric acid by carbonyl reducing enzymes Chem Biol Interact. 2016 Oct 25;258:153-8. doi: 10.1016/j.cbi.2016.09.001.
|
3 |
The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy. 2013 Feb;33(2):210-22. doi: 10.1002/phar.1194.
|
4 |
Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
|
5 |
Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
|
6 |
Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467.
|
7 |
Predicting the environmental emissions arising from conventional and nanotechnology-related pharmaceutical drug products. Environ Res. 2021 Jan;192:110219. doi: 10.1016/j.envres.2020.110219.
|
8 |
The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models. Front Pharmacol. 2021 Aug 6;12:660490. doi: 10.3389/fphar.2021.660490.
|
9 |
Targeting Peroxisome Proliferator-Activated Receptor- (PPAR- ) to reduce paclitaxel-induced peripheral neuropathy. Brain Behav Immun. 2021 Mar;93:172-185. doi: 10.1016/j.bbi.2021.01.004.
|
10 |
Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes Fundam Appl Toxicol. 1995 Jun;26(1):63-74. doi: 10.1006/faat.1995.1075.
|
11 |
The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
|
12 |
In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
|